NCCTG N9831 May 2005 Update  
   
  1. Targeted Adjuvant Systemic Therapy of Breast Cancer
  2. Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel +/- Trastuzumab as Adjuvant
  3. Clinical Research Goals
  4. Study Schema
  5. Eligibility
  6. Clinical Endpoints
  7. Statistical Plan Addition of H to AC -> T
  8. Statistical Plan Timing of H Initiation
  9. Cardiac Testing
  10. Impact of Joint Analysis on N9831 (April 2005)
  11. Patient/Event Status at Time of Joint Analysis (April 2005)
  12. Patient and Tumor Characteristics
  13. Results Disease-Free Survival
  14. Disease-Free Survival: A vs C From the Joint Analysis
  15. Disease-Free Survival: A vs B N9831
  16. Disease-Free Survival: B vs C N9831
  17. Overall Survival
  18. Other Relevant Factors for Patient Management
  19. HER2 Testing in N9831
  20. Cardiac Monitoring Plan
  21. Effect of the Introduction of H on Cardiac Tolerability
  22. Effect of Introduction of Traztusumab on Disease Recurrence
  23. N9831 -- Future Plans
  24. NCCTG N9831 Collaborative Team

Peter A Kaufman, MD